290 related articles for article (PubMed ID: 22570363)
1. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder.
Bonaventure P; Dugovic C; Kramer M; De Boer P; Singh J; Wilson S; Bertelsen K; Di J; Shelton J; Aluisio L; Dvorak L; Fraser I; Lord B; Nepomuceno D; Ahnaou A; Drinkenburg W; Chai W; Dvorak C; Sands S; Carruthers N; Lovenberg TW
J Pharmacol Exp Ther; 2012 Aug; 342(2):429-40. PubMed ID: 22570363
[TBL] [Abstract][Full Text] [Related]
2. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents.
Bonaventure P; Kelly L; Aluisio L; Shelton J; Lord B; Galici R; Miller K; Atack J; Lovenberg TW; Dugovic C
J Pharmacol Exp Ther; 2007 May; 321(2):690-8. PubMed ID: 17314195
[TBL] [Abstract][Full Text] [Related]
3. Translational neurophysiological markers for activity of the metabotropic glutamate receptor (mGluR2) modulator JNJ-40411813: Sleep EEG correlates in rodents and healthy men.
Ahnaou A; de Boer P; Lavreysen H; Huysmans H; Sinha V; Raeymaekers L; Van De Casteele T; Cid JM; Van Nueten L; Macdonald GJ; Kemp JA; Drinkenburg WH
Neuropharmacology; 2016 Apr; 103():290-305. PubMed ID: 26686390
[TBL] [Abstract][Full Text] [Related]
4. Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats.
Ivarsson M; Paterson LM; Hutson PH
Eur J Pharmacol; 2005 Oct; 522(1-3):63-71. PubMed ID: 16223479
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.
Luthringer R; Toussaint M; Schaltenbrand N; Bailey P; Danjou PH; Hackett D; Guichoux JY; Macher JP
Psychopharmacol Bull; 1996; 32(4):637-46. PubMed ID: 8993085
[TBL] [Abstract][Full Text] [Related]
6. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
7. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.
Barbanoj MJ; Clos S; Romero S; Morte A; Giménez S; Lorenzo JL; Luque A; Dal-Ré R
Neuropsychobiology; 2005; 51(3):134-47. PubMed ID: 15838185
[TBL] [Abstract][Full Text] [Related]
8. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
[TBL] [Abstract][Full Text] [Related]
9. The effect of escitalopram on sleep problems in depressed patients.
Lader M; Andersen HF; Baekdal T
Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
[TBL] [Abstract][Full Text] [Related]
10. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
11. 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern.
Hedlund PB; Huitron-Resendiz S; Henriksen SJ; Sutcliffe JG
Biol Psychiatry; 2005 Nov; 58(10):831-7. PubMed ID: 16018977
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
13. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.
Leiser SC; Iglesias-Bregna D; Westrich L; Pehrson AL; Sanchez C
J Psychopharmacol; 2015 Oct; 29(10):1092-105. PubMed ID: 26174134
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression.
Kluge M; Schüssler P; Steiger A
Eur Neuropsychopharmacol; 2007 Jul; 17(8):527-31. PubMed ID: 17337164
[TBL] [Abstract][Full Text] [Related]
15. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
17. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
18. The effects of galantamine and buspirone on sleep structure: Implications for understanding sleep abnormalities in major depression.
Biard K; Douglass AB; De Koninck J
J Psychopharmacol; 2015 Oct; 29(10):1106-11. PubMed ID: 26259773
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
[TBL] [Abstract][Full Text] [Related]
20. The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.
Sarkisyan G; Roberts AJ; Hedlund PB
Behav Brain Res; 2010 May; 209(1):99-108. PubMed ID: 20097233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
